Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE Trial for mCRPC
NCT03110588Phase 1Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2018
- Primary completion
- Dec 2019
- Modality
- Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of prednisone, Abiraterone Acetate Tablets (I), cabazitaxel ginsenoside liposome injection and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Maximum Tolerated Dose up to 2 years. Planned start May 2018; status: withdrawn.
02
Drugs
prednisoneAbiraterone Acetate Tablets (I)cabazitaxel ginsenoside liposome injectionenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03110588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03110588.